TDLNs contain tumour specific PD-1+ T cells co-localising with PD-L1 expressing myeloid cells, including cDCs. Selective targeting of PD-L1 TDLN-resident T cells affects a systemic anti-tumour immune response and tumour control. The gene discussed is CD274; the disease is neoplasm.